title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Results | PMC10318767 | |||
Determination of the optimal cut-off value | ALRI | The optimal cut-off values for lactate dehydrogenase, alkaline phosphatase, De Ritis ratio, APRI, ALRI, ANRI, and APPRI were 191.00, 102.00, 1.52, 0.12, 7.50, 3.18, and 0.46, respectively (Supplementary Fig. The associations between preoperative serum liver enzyme markers and clinicopathological features were presented... | PMC10318767 | |
Development and validation of prognostic nomograms for predicting OS and DFS in patients with stage II/III CRC | tumor, CRC | TUMOR, COLORECTAL CANCER | Next, nomograms that incorporated De Ritis ratio and significant clinicopathological features (age, gender, CEA, CA19-9, tumor location, pathological classification, differentiation degree, histological classification, TNM stage, tumor diameter, preoperative chemotherapy, and radiotherapy) were developed, which aimed t... | PMC10318767 |
Clinical utility of the prognostic nomograms | CRC | The decision curve analyses were conducted to determine the clinical utility of the nomograms by quantifying the net benefits at different threshold probabilities. The decision curves for the nomogram in the training set indicated that when the threshold probabilities of the OS and DFS prediction were in the range of 1... | PMC10318767 | |
Discussion | gallstones, tumor, cancers, death, CRC, fatty liver, ALRI, cirrhosis, human malignancies, hepatobiliary disorders, heart, skeletal muscle, mitochondrial dysfunction | GALLSTONES, TUMOR, CHOLECYSTITIS, CANCERS, RECURRENCE, FATTY LIVER, CIRRHOSIS, HEPATOBILIARY DISORDERS, MICROSATELLITE INSTABILITY, ACUTE VIRAL HEPATITIS, GALLBLADDER POLYPS, MITOCHONDRIAL DYSFUNCTION | Serum liver enzyme markers, as readily-available and non-invasive clinical parameters, have great potential for predicting the prognosis of human malignancies. Our study, for the first time, comprehensively evaluated the prognostic values of lactate dehydrogenase, alkaline phosphatase, De Ritis ratio, APRI, ALRI, ANRI,... | PMC10318767 |
Conclusions | CRC | Our study demonstrates that De Ritis ratio has the ability to independently predict the prognosis of patients with stage II/III CRC. The nomograms incorporating De Ritis ratio and clinicopathological features show higher accuracy, improved discrimination, and greater clinical utility in terms of personalized survival p... | PMC10318767 | |
Acknowledgements | Not applicable. | PMC10318767 | ||
Authors’ contributions | Yanlong Liu and Yashuang Zhao designed the study. Jinming Fu, Fenqi Du, Tian Tian, Yupeng Liu, Ding Zhang, Lijing Gao, and Ting Zheng contributed to the generation, collection, assembly, analysis and/or interpretation of data. Jinming Fu, Hao Huang, Dapeng Li, and Lei Zhang performed the statistical analysis. Jinming F... | PMC10318767 | ||
Funding | Cancer | ONCOLOGY, CANCER | This study was supported by grants from the Beijing Xisike Clinical Oncology Research Foundation (Y321MX2016-045), the Heilongjiang Sunshine Health Foundation (H21L0802), the Post-doctoral Scientific Research Developmental Fund of Heilongjiang (LBH-Q18085), and the Harbin Medical University Cancer Hospital Preeminence ... | PMC10318767 |
Availability of data and materials | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10318767 | ||
Declarations | PMC10318767 | |||
Ethics approval and consent to participate | Cancer | CANCER | This study complied with the standards of the Helsinki Declaration. The study involving human participants was conducted under the supervision of the Ethics Committee of the Harbin Medical University Cancer Hospital. The data for analysis were obtained from retrospective medical records. We have processed the data and ... | PMC10318767 |
Consent for publication | Not applicable. | PMC10318767 | ||
Competing interests | The authors declare no competing interests. | PMC10318767 | ||
References | PMC10318767 | |||
Introduction | obesity | OBESITY | Quality of life (QoL) is a comprehensive and multidimensional construct including several domains of subjective experiences such as physical ability, psychological well-being, social interactions, and school performance [Emotional eating defined as eating as a response from negative or overwhelming feelings is highly p... | PMC10746571 |
Methods | The present cross-sectional study is based on baseline questionnaire data from the COPE-study, which is a nonrandomized controlled trial (Briefly, participating children were recruited in collaboration with two well-established multicomponent lifestyle camps in Denmark. Children from 7-14 years of age, who struggle wit... | PMC10746571 | ||
Measurements | obesity, overweight | OBESITY | Background characteristics, e.g., sex and household income per year, were assessed by a self-developed parent-reported questionnaire. Camp staff measured body weight (kg) and height within the first week of camp. Body weight (kg) was measured according to standard procedures using a bioelectric impedance (InBody model ... | PMC10746571 |
The pediatric quality of life inventory questionnaire (PedsQL 4.0) | QoL was measured using the validated Danish translation of the Pediatric Quality of Life Inventory 4.0 questionnaire (PedsQL 4.0.), and permission to use the PedsQL questionnaire was granted by the original author [ | PMC10746571 | ||
Child eating behavior questionnaire (CEBQ) | eating behaviors, satiety, slowness | The original Child Eating Behavior Questionnaire (CEBQ) [CEBQ contains 35 questions subdivided into eight different eating behaviors: food responsiveness, enjoyment of food, desire to drink, satiety responsiveness, slowness in eating, food fussiness, emotional undereating, and emotional overeating [ | PMC10746571 | |
Statistical analysis | REGRESSIONS | Children were excluded from the present study if they did not answer the PedsQL questionnaire and the CEBQ at baseline. Data from the CEBQ did not fulfill the assumption of linearity, and therefore, the EOE-score and the FR-score were categorized into three categories: “Low” (score ≤ 2), “Medium” (score > 2–3), and “Hi... | PMC10746571 | |
Results | In total, 322 children were invited to participate and 236 children accepted the invitation. Seven children withdrew from the study before or during camp, 93 children were non-participants, while 45 children were excluded due to missing data (Fig. Flowchart of the study participantsIncluded children (Participant charac... | PMC10746571 | ||
Discussion | QoL impairment, overeating with loss of control), disordered eating, binge eating | Based on the results of the present study, QoL is associated with EOE in 7-14-year old children. Children with a high tendency of EOE had a lower QoL compared to children with a lower tendency of EOE. However, due to the study design, it was not possible to determine causality.The present findings are essential in line... | PMC10746571 | |
Strengths and limitations | Despite the novelty of the findings in the present study, some limitations are obvious. The representativeness of the target population is to some degree questionable as children attending camp has a slightly different social background (e.g., more children live with a single parent) and higher morbidity compared to ch... | PMC10746571 | ||
Acknowledgements | The authors thank Julemærkefonden and the multicomponent lifestyle camps in Hobro and Fjordmark for collaborating on this study. | PMC10746571 | ||
Authors’ contributions | IA, DJ, and JB designed this study; DJ collected the data; IA performed the statistical analysis and wrote the initial manuscript. DJ and JB critically revised the manuscript. IA and DJ had the primary responsibility for the final content. All authors have read and agreed to the published version of the manuscript. | PMC10746571 | ||
Funding | Diabetes | DIABETES | Open access funding provided by Aarhus University Hospital This research was funded by Steno Diabetes Center Aarhus (SDCA) which is partially funded by an unrestricted donation from the Novo Nordisk Foundation, Sygeforsikringen “danmark,” and Arla Foods Amba (unrestricted grant). | PMC10746571 |
Availability of data and materials | The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. | PMC10746571 | ||
Declarations | PMC10746571 | |||
Ethics approval statement | -20 | The local Committee of Ethics have approved all parts of the COPE-study (journal number: 1–10-72–73-20). The COPE-study was performed in accordance with good clinical practice and conformed to the Declaration of Helsinki. | PMC10746571 | |
Consent to participate | Parents/guardians provided written consent for their child to participate in the study. | PMC10746571 | ||
Consent for publication | Not applicable. | PMC10746571 | ||
Competing interests | The authors declare no competing interests. | PMC10746571 | ||
References | PMC10746571 | |||
Background | overweight, ® | OBESE | Obex® may be helpful in reducing body weight and fat. The current study was carried out to evaluate the efficacy and safety of Obex® in the treatment of overweight and obese subjects. | PMC9940432 |
Methods | overweight | OBESE | A double-blind, randomised, controlled phase III clinical trial was conducted involving 160 overweight and obese subjects (BMI ≥ 25.0 and < 40 kg/m | PMC9940432 |
Results | After 3 months of Obex®, 48.3% of the participants (28/58) achieved complete success in reducing both weight and waist circumference by greater than or equal to 5% from baseline, as opposed to 26.0% (13/50) of individuals receiving placebo ( | PMC9940432 | ||
Conclusions | obesity, ® | OBESITY | The consumption of Obex® together with lifestyle changes increased HDL-c, contributed to a rapid reduction of weight and waist circumference, as well as improved insulin homeostasis, which did not occur in the placebo group, and appears to be safe as an adjunct at conventional obesity treatment. | PMC9940432 |
Trial registration | Clinical trial protocol was registered in the Cuban public registry of clinical trials under code RPCEC00000267 on 17/04/2018 and also registered in the international registry of clinical trials, ClinicalTrials.gov, under code: NCT03541005 on 30/05/2018. | PMC9940432 | ||
Keywords | PMC9940432 | |||
Introduction | Obesity, obesity, T2D, obese, ®, medicantions, impaired fasting glucose, prediabetes, overweight, metabolic syndrome | OBESITY, OBESITY, OBESE, ADVERSE EVENTS, PREDIABETES, INSULIN RESISTANCE, METABOLIC SYNDROME, INSULIN SENSITIVITY | The incidence of overweight and obesity has reached epidemic levels and represents a major serious threat to public health on a global scale [Obesity is a major risk factor for T2D and prediabetes [In the United States of America, the age-adjusted prevalence of overall obesity increased from 35.4% in 2011–2012 to 43.4%... | PMC9940432 |
Material and methods | PMC9940432 | |||
Participants | sepsis, eating disorders, prediabetes, thyroid dysfunction, overweight, hypo-, acromegaly, type 2 diabetes, hypersensitivity | SEPSIS, OBESE, DISEASE, TYPE 1 DIABETES, CHRONIC DISEASES, DISORDERS, PREDIABETES, THYROID DYSFUNCTION, HYPERTHYROIDISM, HYPERCORTISOLISM, INSULIN RESISTANCE, ASYMPTOMATIC HYPOGLYCAEMIA, HYPERSENSITIVITY, ACROMEGALY, TYPE 2 DIABETES, DISEASES | Subjects were recruited through written advertisements contained in brochures produced for the study. The clinical trial was also promoted through direct communication and via opportunistic population screening in overweight and obese subjects.Participants were included if they were aged 20–60 years, had a BMI ≥ 25.0 k... | PMC9940432 |
Sample size estimation | The estimation of the sample size was based on the rate of weight reduction with non-pharmacological treatment (diet and physical activity) is approximately 15% (p1) and it is assumed that we want to achieve a success rate of 35% (p2) in the experimental group (patients with Obex® treatment), i.e. we aim to detect a di... | PMC9940432 | ||
Ethical considerations | ® | The study protocol was approved by the Research and Ethics Committee of the Cuban Endocrinology Institute and was conducted following the Declaration of Helsinki. Obex® is registered as a nutritional supplement with the National Institute of Nutrition and Food Hygiene in Havana, Cuba. Written consent was obtained from ... | PMC9940432 | |
Study design and dietary supplementation regimen | obese, overweight, Diabetes | OBESE, DIABETES | The present study was a randomised double-blind parallel-group placebo-controlled phase III trial performed at the Institute of Endocrinology, Havana, Cuba, in overweight and obese adults who met the selection criteria.After an initial evaluation, all subjects who met the eligibility criteria and wanted to participate ... | PMC9940432 |
Study product | The dietary supplement Obex® used in this study was supplied by Laboratorios Catalysis. This product is marketed as a food supplement by Laboratorios Catalysis (Macarena, no. 14 28,016 Madrid, Spain). The sachets of Obex® (4 g) contained the ingredients specified in Table Qualitative-quantitative composition of Obex®Nu... | PMC9940432 | ||
Adverse events | diarrhoea, nausea, bloating, dyspepsia, headache, rashes | ADVERSE EVENTS, ADVERSE EVENT | Every one and a half months, a clinical examination of the participants was performed to determine whether they experienced any adverse events. Adverse events such as rashes, headache, diarrhoea, nausea, dyspepsia, and bloating were recorded. | PMC9940432 |
Physical examination | BLOOD, CREST | The physical examination included assessments of height, weight, waist and hip circumference, and blood pressure. The physical assessments were performed at baseline, 3 and 6 months after starting Obex® or placebo.Height and weight were measured, and body mass index (BMI) was calculated as weight (kg) divided by height... | PMC9940432 | |
Laboratory tests | BEN | INSULIN SENSITIVITY, INSULIN RESISTANCE, INSULIN SENSITIVITY | At the start of the study (baseline) and six months, venous blood samples were collected after an overnight fast for biochemical assessments: fasting plasma glucose, lipid profile (total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol), creatinine, uric acid and hepatic enzymes, as well as a second bloo... | PMC9940432 |
Outcomes | INSULIN RESISTANCE, INSULIN SENSITIVITY | The primary outcome was a change in anthropometric measurements and glucose, insulin and lipid concentrations, as well as variations in insulin release, insulin resistance, and insulin sensitivity. Secondary outcomes were variation in serum creatinine, uric acid, hepatic enzymes and change in blood pressure. The change... | PMC9940432 | |
Statistical analysis | Data were expressed as mean ± standard deviation and as percentages for categorical variables (before and after). Differences between groups (Obex® and placebo) were analysed by Mann–Whitney nonparametric independent sample test.Wilcoxon signed-rank tests were used to compare changes between baseline and the end of tre... | PMC9940432 | ||
Acknowledgements | The authors would like to thank the staff at the Biochemistry Laboratory, Institute of Endocrinology, for their excellent collaboration. Special thanks to Eduardo Sanz (Catalysis, S.L.) for his helpful comments. And finally, we are grateful to the patients for participating in this trial. | PMC9940432 | ||
Authors’ contributions | REV, JRA, ADRR | JRA | Conceptualisation, methodology, investigation, writing – preparation and writing of the original draft – review & editing, ECR, ICD, JRA, JCH, AICG, YAD, JHR and SMJ; software, ECR; data curation, JRA and TMGC; JVR, AAA, ADRR and REV, formal analysis; visualisation, LJE and YAR; supervision, JRA, ZBB and ESE; project a... | PMC9940432 |
Funding | This research was partly funded by Catalysis, S.L. (Madrid, Spain), which provided both products (Obex® and placebo) used for the trial. | PMC9940432 | ||
Availability of data and materials | The datasets used and/or analysed during the current study available from the corresponding author on reasonable request. | PMC9940432 | ||
Declarations | PMC9940432 | |||
Ethics approval and consent to participate | ® | The study protocol was approved by the Research and Ethics Committee of the Cuban Endocrinology Institute and was conducted following the Declaration of Helsinki. Obex® is registered as a nutritional supplement with the National Institute of Nutrition and Food Hygiene in Havana, Cuba. Written consent was obtained from ... | PMC9940432 | |
Consent for publication | Not applicable. | PMC9940432 | ||
Competing interests | The authors declare no conflicts of interest. The authors are responsible for the content and writing of the article. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation. | PMC9940432 | ||
References | PMC9940432 | |||
Aim | GESTATIONAL DIABETES | To determine the effectiveness of despatching an electronic reminder of participation in screening for gestational diabetes. The reminder was sent to the women 1–8 years after delivery. | PMC9872380 | |
Methods | GESTATIONAL DIABETES | A registry-based, randomized controlled trial in the North Denmark Region among women with gestational diabetes. Randomization was made, which included seven groups stratified by the child’s birth year (2012–2018). The intervention group received standard care supplemented by an electronic reminder through a secure nat... | PMC9872380 | |
Results | multiparity | TYPE 2 DIABETES | A total of 471 (32.1%) women participated in screening. The primary outcome was experienced by 257 women (35.1%) in the intervention group and 214 women (29.2%) in the control group. The effect of the reminder seemed to increase with recipient’s age, non-western origin, urban dwelling, and multiparity. Of those who par... | PMC9872380 |
Conclusion | Electronic reminders, based on the principles of informed choice and patient-centred care, to women have been shown to support life-long participation in follow-up screening. Attempts to further stimulation of coverage could however be considered. | PMC9872380 | ||
Trail registration | ISRCTN registry (22/04/2022, ISRCTN23558707). | PMC9872380 | ||
Keywords | PMC9872380 | |||
Introduction | GDM, gestational diabetes | GDM, GESTATIONAL DIABETES | The prevalence of gestational diabetes (GDM) varies regionally, thus affecting approximately 7–8% of pregnancies in Europe [Although reminder interventions have been found effective in targeting some of the many documented barriers to follow-up screening after birth, the effect varies strongly across settings [As previ... | PMC9872380 |
Materials and methods | PMC9872380 | |||
Study design and participants | PMC9872380 | |||
Design and setting | This study was designed as a two-armed, single-blinded randomized controlled trial. The setting was the North Denmark Region, with approximately 0.6 million inhabitants [ | PMC9872380 | ||
Participants | PMC9872380 | |||
Inclusion and exclusion criteria | GDM | GDM | Women who had given birth between 2012 and 2018 and were diagnosed with GDM were eligible for inclusion. Diagnostic test during pregnancy consists of an oral glucose tolerance test (OGTT) with diagnostic criteria of a 2-h blood glucose (≥ 9.0 mmol/l) [ | PMC9872380 |
Identification and data sources | death | Women were identified via the National Patient Register, which is based on all hospital admissions in Denmark, contains personal information on patients, including CPR number, home municipality, age, parity (primipara or multipara), BMI and death [ | PMC9872380 | |
Sample size | The sample size was determined on the basis of a risk difference calculation. Based on participation rates in the region and a reminder intervention achieving an effect above 10% points [ | PMC9872380 | ||
Study intervention | noninsulin-treated GDM, GDM, type 2 diabetes mellitus, insulin-treated GDM | GDM, TYPE 2 DIABETES MELLITUS | In the setting of the North Denmark region, women with a pregnancy complicated by GDM are routinely informed by a nurse or midwife about the increased risk of type 2 diabetes mellitus and the recommendation of follow-up screening after birth. If the woman has insulin-treated GDM, an appointment for the first screening ... | PMC9872380 |
Randomization | GDM | GDM | The study population was stratified on the calendar year for the GDM pregnancy, based on the birth year of the child. An independent statistician was tasked with randomization into either intervention group or control group within each stratum using R Core Team software (2020) [ | PMC9872380 |
Outcome assessment | GDM, diabetes | GDM, DIABETES | The primary outcome was any participation in follow-up screening after receiving a reminder, defined as the performance of the recommended blood test for diabetes. In general practice, HbA1c are the recommended diagnostic test used for women with previous GDM [ | PMC9872380 |
Data analysis | ®, diabetes | DIABETES | The baseline characteristics of all randomized women were compared descriptively, showing frequency and percentages in total and between the control and intervention groups. Categorizations of baseline characteristics included Age (≤ 25 Years, 26–35 Years, 36–50 Years), Ethnicity (Danish/western, non-western), Employme... | PMC9872380 |
Results | PMC9872380 | |||
Recruitment and participant flow | diabetes | DIABETES | Of the 1708 women assessed for eligibility, 188 had a diabetes diagnosis prior to birth (Fig. Flowchart | PMC9872380 |
Postpartum follow-up and early detection of diabetes | type 2 diabetes mellitus | EVENT, TYPE 2 DIABETES, TYPE 2 DIABETES MELLITUS, SECONDARY | Screening involved 471 (32.1%) women. The primary outcome event was experienced by 257 women (35.1%) in the intervention group and 214 women (29.2%) in the control group. We demonstrated a 20% increased chance of participation in screening in the intervention group (RR: 1.20; 95% CI 1.03–1.39) and a 5% increase in abso... | PMC9872380 |
Identified harms | No significant harms were identified as a result of the study. | PMC9872380 | ||
Discussion | PMC9872380 | |||
Key results | GDM | GDM, RECRUITMENT | This study demonstrates a significant increase in participation in screening among women with prior GDM who receive an email reminder in comparison with women who receive only standard care. Our results thereby corroborate the growing body of evidence that reminding women to be screened after birth are effective [Conte... | PMC9872380 |
Strengths and limitations | GDM | MINOR, EVENT, GDM, SECONDARY, TYPE 2 DIABETES MELLITUS | The simple study design, with its adaptation to existing system resources, ensured the inclusion of practically all cases and high follow-up rates. The validity of the Danish National Patient Register database enabled the identification of women with a GDM diagnosis, lending strong support to our expectation that women... | PMC9872380 |
Implications for practice and research | GDM, diabetes | GDM, IMPAIRED GLUCOSE TOLERANCE, DIABETES | We urge general practice clinics to continue to strengthen attempts to engage in the decision-making process with women and support knowledge transfer between healthcare sectors. Such challenges appear to have diminished the effect of the reminder, creating a barrier to follow-up screening. Even if the reminder were ro... | PMC9872380 |
Conclusion | Electronic reminders to women can support the recommendation of participation in follow-up screening, as this study test found that a reminder beyond the first 12 months after birth are effective in increasing women’s participation in screening. The reminder is based on the principles of informed choice and patient-cen... | PMC9872380 | ||
Acknowledgements | The research was funded by the Department of Midwifery and the Sustainable Science research programme at University College of Northern Denmark, the Department of Health Science and Technology, Aalborg University, and the Clinical Nursing Research Unit, Aalborg University Hospital. The academic work was also supported ... | PMC9872380 | ||
Authors’ contributions | JHN, KF, JKK and CO all contributed to development of the study protocol. KF retrieved the register data. Supported by KF, JHN was responsible for organizing the despatch of the reminder and conducted the data analysis. JHN wrote the first draft of the paper while KF, JKK and CO contributed to interpretation of data. T... | PMC9872380 | ||
Funding | This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. | PMC9872380 | ||
Availability of data and materials | All data generated or analysed during this study are included in this published article. | PMC9872380 | ||
Declarations | PMC9872380 | |||
Ethics approval and consent to participate | The Danish science ethics committee of the North Denmark Region, Denmark was approached and it waived the need for ethics approval as well as informed consent. The study thereby adheres to Danish legislation [ | PMC9872380 | ||
Consent for publication | Not applicable. | PMC9872380 | ||
Competing interests | The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. | PMC9872380 | ||
References | PMC9872380 | |||
Introduction | peripheral nerve block | VASODILATION, COLD, VASODILATATION, COMPLICATION | The results of the pinprick and cold tests performed on the arm, forearm, and wrist-wrist areas of patients scheduled for upper extremity procedures are subjective and dependent on patient’s compliance. The purpose of this study was to determine whether the perfusion index (PI) could be used as an objective indicator t... | PMC10171442 |
Materials and methods | nerve injury, thumb abduction, infections, pain, diabetes, peripheral vascular disease, allergies | INFILTRATION, INFECTIONS, ALLERGIES | The study was conducted at the Adıyaman University Research and Training Hospital between 01 August 2021 and 15 April 2022.The study included 50 patients between the ages of 18 and 65 years who were in the American Society of Anesthesiologists (ASA) I–II group and were scheduled for upper extremity surgery (hand, wrist... | PMC10171442 |
Ethical statement | This study was conducted in accordance with the principles of the Helsinki Declaration and all applicable national regulations and institutional policies (as revised in 2013). This study was reviewed and approved by Adıyaman University Clinical Studies Ethics Committee (decision date: 23/06/2020, decision number: 2020/... | PMC10171442 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.